Overview: Endomysial Antibody IgA Panel
Introduction: The Endomysial Antibody IgA Panel is a diagnostic tool designed to screen for celiac disease using serum samples. In India, celiac disease prevalence is ~0.5-1 percent (higher in northern wheat-consuming states), with endomysial IgA (EMA IgA) as highly specific marker for villous atrophy. High morbidity from underdiagnosis in rural/low-SES patients with chronic diarrhea, anemia, growth failure, limited serology access, delayed gluten-free diet leading to malnutrition or lymphoma risk. Per gastroenterology practices aligned with ICMR and Indian Society of Gastroenterology guidelines, the test employs immunoassay for EMA IgA (qualitative) over 1-2 days with high specificity, valuable as confirmatory after anti-tTG screening. This diagnostic falls under autoimmune screening and targets patients with GI symptoms, iron deficiency, or family history, addressing accurate detection to guide duodenal biopsy and diet. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing complications. Its serum-based approach ensures reliable detection.
Other Names: Endomysial IgA Pnl.
FDA Status: FDA approved, CLIA certified for immunology, compliant with 2025 standards.
Historical Milestone: EMA IgA high-specificity marker; in India, used in celiac clinics.
Purpose: The test assesses 2 parameters including endomysial IgA to guide celiac disease screening, detect autoimmunity, inform biopsy/diet.
Test Parameters: 1. Endomysial IgA, 2. Qualitative Result.
Pretest Condition: No fasting required; patients should report diarrhea, anemia, or gluten intolerance.
Specimen: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.
Medical History: Patients should provide details on GI symptoms, growth issues, family celiac history.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated celiac including malabsorption, benefits of early detection, and minimal discomfort from venipuncture.
Procedural Considerations: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, hemolysis, or IgA deficiency can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Positive EMA IgA indicates celiac disease, necessitating specialist input. Negative may require follow-up if symptoms persist.
Specialist Consultation: Gastroenterologists should be consulted for management.
Additional Supporting Tests: Anti-tTG IgA, duodenal biopsy for confirmation.
Test Limitations: Requires IgA sufficiency; comprehensive approach required.
References: Indian Journal of Gastroenterology 2024, Celiac Studies India 2023.
